Symbollon Pharmaceuticals

Symbollon is a specialty pharmaceutical company focused on the development and commercialization of proprietary drugs based on its I2 technology. I2 is the chemical symbol for molecular iodine. Molecular iodine is the active species of iodine, a proven fast acting, broad-spectrum antimicrobial and therapeutic. Formed in 1986, Symbollon completed its initial public offering in December 1993. Since that time we have pursued product applications for our technology in two distinct areas; women’s healthcare and antimicrobial applications. In female health, Symbollon has developed a proprietary oral tablet based on our technology that generates I2 in situ (the stomach of the patient). We refer to this drug as IoGen. In 2000, Symbollon completed Phase I and II clinical trials evaluating IoGen as a potential treatment for fibrocystic breast disease. Phase III pivotal trials will be conducted in 2005. We believe that IoGen may also be useful for the treatment and prevention of other types of excess cell growth in female reproductive tissue, such as endometriosis, ovarian cysts and pre-menopausal breast cancer. Our efforts in infection control have resulted in one commercial product to date. Launched in 1995, IodoZyme is a bovine teat sanitizer sold through our marketing partner, West Agro, Inc. In the future, Symbollon intends to investigate the potential effectiveness of its technology in such antimicrobial applications as dermatology, oral care, urinary tract infection and wound care.

Contact Details: 37 Loring Drive Framingham Massachusetts 01702 United States of America Tel: (508) 620-7676 Fax: (508) 620-7111 Email: pd1@symbollon.com WWW: www.symbollon.com/

Loading...

Recent Publications by Symbollon Pharmaceuticals:
Factors influencing the study of peroxidase-generated iodine species and implications for thyroglobulin synthesis. A key issue in the mechanism of thyroglobulin (Tg) iodination by...	4th October, 2008	Symbollon Pharmaceuticals, Inc., Framingham, Massachusetts, USA.	Thyroid. 2008 Jul;18(7):769-74. DOI Direct Link
Aqueous iodine equilibria in Mammalian iodination reactions. Regulatory activity has been demonstrated in two classes of iodinated...	30th August, 2008	Symbollon Pharmaceuticals, Inc., Framingham, Massachusetts 01702, USA.	Thyroid. 2007 Jan;17(1):19-24. DOI Direct Link
The effect of supraphysiologic levels of iodine on patients with cyclic mastalgia. A randomized, double-blind, placebo-controlled, multicenter clinical trial...	4th March, 2005	Symbollon Pharmaceuticals, Inc., Framingham, Massachusetts 01702, USA.	Breast J. 2004 Jul-Aug;10(4):328-36. DOI Direct Link

BioNews Results for Symbollon Pharmaceuticals:
Symbollon Pharmaceuticals Inc-Financial Company Report - research report released	PR inside:  Nov 2 2009 9:33PM Matching: symbollon pharmaceuticals
Symbollon Pharmaceuticals Inc-Therapeutic Competitors - research report released	PR inside:  Oct 28 2009 12:30PM Matching: symbollon pharmaceuticals

Symbollon Pharmaceuticals (SYMBA.OB) Financial information Links from Barchart
SYMBA.OB Quote from from Barchart.com
SYMBA.OB Chart from from Barchart.com
SYMBA.OB Profile from from Barchart.com
SYMBA.OB Opinion from from Barchart.com
→View more Symbollon Pharmaceuticals finance information.

Contact BioPortfolio for a quote for a customised Excel verision of BioCorporate or BioEmail databases.

This page has been viewed 358 times since April 2007, the link to the organisation's website has been followed 39 times

Recent Search Terms used to find this page: symbollon 2009 | symbollon pharmaceuticals | .

Search for more companies in Framingham

Search for more companies in Massachusetts

This site uses Thumbshots previews, resources from the NCBI applied. Maps are centred on zip/postcodes and should not be relied upon for exact building locations. Some information on this page has been collected automatically and may not have been verified.
BioPortfolio search results for Symbollon Pharmaceuticals